HOVERINK BIOTECHNOLOGIES APPOINTS VSTOCK TRANSFER, LLC AS ITS TRANSFER AGENT AND REGISTRAR
July 11, 2018 10:24 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 11, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES Appoints VSTOCK TRANSFER, LLC as its TRANSFER AGENT AND REGISTRAR Hoverink Biotechnologies is currently developing IV and...
LADAVRU® NEWS “HOVERINK BIOTECHNOLOGIES SEEKS COMMERCIAL PARTNERING OPPORTUNITIES IN ONCOLOGY SUPPORTIVE THERAPIES AND SEEKS A COMMERCIALIZATION AGREEMENT FOR ITS INVESTIGATIONAL DRUG LADAVRU®”
July 05, 2018 19:20 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, July 05, 2018 (GLOBE NEWSWIRE) -- HOVERINK BIOTECHNOLOGIES, seeks to enter into a licensing agreement for the exclusive rights to commercialize LADAVRU(TM) (Dronabinol for...
LADAVRU® RECEIVES APPROVED FOR PUBLICATON NOTICE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HOVERINK BIOTECHNOLOGIES ANNOUNCES.
April 29, 2018 18:53 ET
|
Hoverink Biotechnologies, Inc
LOS ANGELES, CA, April 29, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it has received its Notice of publication from the UNITED STATES PATENT AND TRADEMARK OFFICE for...